National Institute on Drug Abuse:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:National Institute on Drug Abuse - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9327
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
National Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a research institute that provides drug abuse and addiction services. The institute offers services in drugs of abuse such as bath salts, cocaine, heroin, inhalants, alcohol, club drugs, methamphetamine, prescription drugs, commonly abused drugs, emerging trends, salvia, and tobacco addiction, among others. It also offers services in addiction science, drug testing, drugged driving, global health, hepatitis, comorbidity, criminal justice and drug abuse areas. The institute operates AIDS research program, international program, and intramural research program, among others. NIDA is headquartered in Bethesda, Maryland, the US.

National Institute on Drug Abuse – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 11
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 12
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 13
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 14
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 15
Licensing Agreements 16
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 16
EncepHeal Therapeutics Enters into Licensing Agreement with National Institute on Drug Abuse 17
National Institute on Drug Abuse – Key Competitors 18
National Institute on Drug Abuse – Key Employees 19
National Institute on Drug Abuse – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Government and Public Interest 21
Oct 31, 2018: Columbia University receives National Institute on Drug Abuse (NIDA) research grant to study impact of medical cannabis on opioid use in collaboration with Columbia Care 21
Sep 24, 2018: MEBIAS Discovery receives grant from NIDA 22
Sep 17, 2018: Ensysce Biosciences receives multi-year NIDA grant to study and deliver opioid overdose protection 23
Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 24
Jul 09, 2018: Study casts doubt on effectiveness of e-cigs for smoking cessation 25
Jun 28, 2018: New clinician screening tool available for substance use 26
Jun 22, 2018: Analysis of insurance coverage for back pain shows missed opportunities to prescribe non-opioid medications 27
Jun 22, 2018: UCLA receives $9.5 million grant to study link between substance use and HIV transmission 28
Jun 19, 2018: Methadone and buprenorphine reduce risk of death after opioid overdose 29
Mar 28, 2018: Study changes long-held concepts of cell decoding 30
Nov 01, 2017: Understanding Addiction in the Adolescent Mind 31
Sep 27, 2017: NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research 33
Sep 27, 2017: Camino Pharma Co-founder Receives $10.8 Million Grant for Development of Potential Drug for Cocaine and Nicotine Addiction 35
Sep 26, 2017: UAMS Neuroscientist Receives Grant to Study Resilience of Brain to Mental Illness 36
Sep 15, 2017: Immune System Linked to Alcohol Drinking Behaviour 37
Sep 05, 2017: Treatment for Opioid or Alcohol Abuse Can Be Successful in Primary Care Settings 39
Aug 01, 2017: Collins, King Announce $185,413 in Funding to the University of New England to Support Addiction Research 41
Apr 19, 2017: EncepHeal Therapeutics Receives $300,000 Grant. 42
Apr 19, 2017: EncepHeal Therapeutics Receives $150,000 Notice of Award from the North Carolina Biotechnology Center. 43
Apr 05, 2017: NIDA announces recipients of 2017 Avant-Garde Awards for HIV/AIDS research 44
Jan 30, 2017: New TSRI Study Shows Early Brain Changes in Fragile X Syndrome 46
Product News 47
Dec 20, 2017: Seven Emmes Employees Recognized in Lancet Study Comparing Two Opioid Treatments 47
Other Significant Developments 48
Aug 31, 2018: Novel intervention halves rate of death among people living with HIV who inject drugs 48
Aug 22, 2018: US government orders 3.6 million SPECTRUM research cigarettes from 22nd Century 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Key Facts 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Drug Abuse, Deals By Therapy Area, 2012 to YTD 2018 9
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 11
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 12
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 13
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 14
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 15
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 16
EncepHeal Therapeutics Enters into Licensing Agreement with National Institute on Drug Abuse 17
National Institute on Drug Abuse, Key Competitors 18
National Institute on Drug Abuse, Key Employees 19

List of Figures
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[National Institute on Drug Abuse:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AusNet Services Ltd (AST):企業の財務・戦略的SWOT分析
    AusNet Services Ltd (AST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bush Industries Inc:企業の戦略・SWOT・財務分析
    Bush Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Bush Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Towngas China Co Ltd (1083):企業の財務・戦略的SWOT分析
    Summary Towngas China Co Ltd (Towngas China), a subsidiary of The Hong Kong and China Gas Co Ltd is an oil and gas company. The company's business activities include sale and distribution of pipeline gas, gas pipeline construction, operation of city-gas pipeline networks, operating fuel automobile r …
  • Harbin Electric Co Ltd (1133):企業の財務・戦略的SWOT分析
    Harbin Electric Co Ltd (1133) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Vision Ease, LP:企業の戦略的SWOT分析
    Vision Ease, LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Euskaltel SA (EKT):企業の財務・戦略的SWOT分析
    Euskaltel SA (EKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • The Aerospace Corp:企業の戦略的SWOT分析
    The Aerospace Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • PixarBio Corp (PXRB)-製薬・医療分野:企業M&A・提携分析
    Summary PixarBio Corp (PixarBio), formerly BMP Holdings Inc., is a biotechnology company that develops novel neurological drug delivery systems for postsurgical pain, acute pain and chronic pain. The company focuses on the research and commercial development of targeted drug delivery systems, device …
  • Bausch & Lomb Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bausch & Lomb Inc (Bausch & Lomb), a subsidiary of Valeant Pharmaceuticals International Inc, is a vision-care company with focus on the protection, enhancement and restoration of eyesight. It offers over-the-counter supplements, eye care products, contact lenses, ophthalmic pharmaceuticals, …
  • Itochu Corporation (8001)-エネルギー分野:企業M&A・提携分析
    Summary Itochu Corporation (Itochu) is a trading company. It offers domestic trading, import and export, and overseas trading. The company trades in products such as textile, machinery, metals, minerals, energy, chemicals, food, general products, information and communications technology, realty, in …
  • TiGenix NV (TIG):医療機器:M&Aディール及び事業提携情報
    Summary TiGenix NV (TiGenix), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products. The company exploits the anti-inflammatory properties of stem cells to develop novel therapies. It offers products such as AlloCSC-0 …
  • VPK Packaging Group NV:企業の戦略・SWOT・財務情報
    VPK Packaging Group NV - Strategy, SWOT and Corporate Finance Report Summary VPK Packaging Group NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Bausch Health Companies Inc (VRX):医療機器:M&Aディール及び事業提携情報
    Summary Bausch Health Companies Inc(Bausch Health) formerly known as Valeant Pharmaceuticals International Inc, develops, manufactures and markets several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, op …
  • Destiny Pharma Plc (DEST):製薬・医療:M&Aディール及び事業提携情報
    Summary Destiny Pharma Plc (Destiny Pharma), formerly Destiny Pharma Ltd, a subsidiary of Destiny Pharma Holdings Ltd is a drug development and discovery company that offers commercial exploitation and clinical development of the antibacterial products. The company provides XF drug platform to addre …
  • GridEdge Networks Inc:企業の戦略的SWOT分析
    GridEdge Networks Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Stantec Inc (STN):電力:M&Aディール及び事業提携情報
    Summary Stantec Inc. (Stantec) is a construction and consulting services company. The company offers architectural, engineering, and environmental services. Its service portfolio includes architecture and interior design, building engineering, community design services, geomatics, geotechnical engin …
  • Norwegian Air Shuttle ASA:企業の戦略・SWOT・財務分析
    Norwegian Air Shuttle ASA - Strategy, SWOT and Corporate Finance Report Summary Norwegian Air Shuttle ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Calgary Scientific Inc-医療機器分野:企業M&A・提携分析
    Summary Calgary Scientific Inc (Calgary Scientific) is a scientific software company that provides technology solutions for the medical industry. The company offers ResolutionMD, a diagnostic medical imaging software solution that acts as an enterprise image viewer for doctors to view patient images …
  • SeaWorld Entertainment, Inc.:企業の戦略・SWOT・財務情報
    SeaWorld Entertainment, Inc. - Strategy, SWOT and Corporate Finance Report Summary SeaWorld Entertainment, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Ferrovial, S.A. (FER):企業の財務・戦略的SWOT分析
    Ferrovial, S.A. (FER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆